Investigating how mitochondrial division affects melanoma and its treatment
Official title: Chronic Mitochondrial Division and Melanoma: Mechanism, Prognosis, and Therapy
Funded at Icahn School of Medicine at Mount Sinai · NIH-11088724 · Data updated 2026-11-12
This study is looking at how changes in tiny parts of cells called mitochondria affect melanoma, with the goal of finding new ways to improve treatment for patients by understanding how their cancer cells work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 15, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $492,409 |
| NIH project number | 5R01CA267696-04 |
| Project ID | NIH-11088724 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with melanoma, particularly those with mutations in the MAPK pathway.
✕Less likely to help
Patients with non-melanoma skin cancers or those without mitochondrial dysfunction may not benefit from this research.
What this research studies
This research explores the role of mitochondrial dynamics in melanoma, focusing on how chronic mitochondrial division can influence cancer cell metabolism and response to therapy. By examining the mechanisms behind mitochondrial dysfunction in cancer cells, the study aims to identify potential therapeutic targets that could improve treatment outcomes. Patients may benefit from insights into how their cancer cells behave and how therapies can be tailored to counteract these effects.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma by targeting mitochondrial dysfunction.
How similar studies have gone: Previous research has shown promising results in targeting mitochondrial dysfunction in various cancers, suggesting that this approach may be effective for melanoma as well.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Chipuk, Jerry Edward — Icahn School of Medicine at Mount Sinai
- Study coordinator: Chipuk, Jerry Edward
Related research
Other NIH-funded projects on the same topics.
-
Chronic mitochondrial division and melanoma: how it drives cancer and how to treat it
A cancer-focused project explores how mitochondrial division affects melanoma and whether targeting this process could improve therapy.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
AI-powered digital pathology to tailor cancer treatment decisions
A team at Emory is building an AI-powered platform that analyzes cancer slides to help doctors choose the right therapies and avoid unnecessary chemotherapy or radiation for patients.
-
Harnessing the body's response to leptospirosis to aid diagnosis and prognosis
This grant aims to develop new ways to detect leptospirosis earlier and predict how severe it might become by studying the body's own response.
-
Harnessing the body’s response to Leptospirosis to improve diagnosis and prognosis
A research program at UCLA aims to use how the body responds to leptospirosis to make better diagnoses and predict outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.